303 results on '"Helen A. Shih"'
Search Results
2. A Systematic Comparison of Dose Distributions Delivered in 125I Plaque Brachytherapy and Proton Radiation Therapy for Ocular Melanoma
- Author
-
Alexei V. Trofimov, Mary E. Aronow, Evangelos S. Gragoudas, Florence K. Keane, Ivana K. Kim, Helen A. Shih, and Mandar S. Bhagwat
- Subjects
Cancer Research ,Radiation ,Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2023
3. Case 36-2022: A 30-Year-Old Woman with Decreased Vision and Headache
- Author
-
Michael, Levy, Bart K, Chwalisz, Benjamin M, Kozak, Michael K, Yoon, Helen A, Shih, and Anna M, Stagner
- Subjects
Adult ,Headache ,Vision Disorders ,Humans ,Female ,General Medicine - Published
- 2022
4. Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline
- Author
-
Lia M. Halasz, Albert Attia, Lisa Bradfield, Daniel J. Brat, John P. Kirkpatrick, Nadia N. Laack, Nafisha Lalani, Emily S. Lebow, Arthur K. Liu, Heather M. Niemeier, Joshua D. Palmer, Katherine B. Peters, Jason Sheehan, Reena P. Thomas, Sujay A. Vora, Daniel R. Wahl, Stephanie E. Weiss, D. Nana Yeboa, Jim Zhong, and Helen A. Shih
- Subjects
Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2022
5. Health-Related Quality of Life Analyses in Nonfunctioning Pituitary Macroadenoma Patients Identifies At-Risk Populations
- Author
-
Amy J. Wisdom, M. Aiven Dyer, Nora K. Horick, Beow. Y. Yeap, Karen K. Miller, Brooke Swearingen, Jay S. Loeffler, and Helen A. Shih
- Abstract
Purpose The quality of life (QoL) impact of multidisciplinary treatment for patients with nonfunctioning pituitary macroadenomas (NFPMA) is unclear. We sought to investigate associations between patient factors, clinical data, and patient-reported QoL in patients with NFPMA. Methods Patients with treated NFPMA and > 1 year of follow up after transsphenoidal surgery (TSS) and with no evidence of progressive disease were evaluated utilizing the following patient-reported outcome measures: RAND-36-Item Health Survey, Multidimensional Fatigue Inventory, Cognitive Failures Questionnaire. Results 229 eligible patients completed QoL questionnaires a median of 7.7 years after initial transsphenoidal surgery (TSS). 25% of participants received radiation therapy (RT) a median of 2.0 years (0.1–22.5) after initial TSS. Patients who received RT were younger (median age 46 v 58, p Conclusion Hypopituitarism, radiation therapy after TSS, and financial stressors are associated with more impaired QoL in patients with NFPMA. Awareness of these factors can better guide use and timing of radiation therapy in addition to identifying patients who can benefit from multidisciplinary surveillance.
- Published
- 2023
6. Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience
- Author
-
Anurag Saraf, Torunn I Yock, Andrzej Niemierko, Kevin S Oh, William T Curry, William E Butler, Deborah A Forst, Isabel Arrillaga-Romany, David H Ebb, Nancy J Tarbell, Shannon MacDonald, Jay S Loeffler, and Helen A Shih
- Subjects
Adult ,Cancer Research ,Adolescent ,Clinical Investigations ,Middle Aged ,Combined Modality Therapy ,Disease-Free Survival ,Young Adult ,Craniospinal Irradiation ,Oncology ,Humans ,Neurology (clinical) ,Cerebellar Neoplasms ,Medulloblastoma ,Retrospective Studies - Abstract
Background Medulloblastoma (MB) is a rare central nervous system malignancy of adults, with limited contemporary studies to define treatment guidelines and expected late toxicity. Methods A single-center, retrospective study was conducted of patients age ≥18 years from 1997–2019 with MB and who were treated with postoperative radiotherapy. Late toxicity was defined as a minimum of 18 months from diagnosis. Overall survival (OS) and progression-free survival (PFS) were characterized using Kaplan-Meier and Cox regression analyses. Results Fifty-nine patients met criteria, with median age of 25 years (range 18–62 y) and median follow-up of 6.5 years (range 0.7–23.1 y). At diagnosis, 68% were standard-risk, 88% Chang M0, and 22% with anaplastic histology. Gross total resection was achieved in 75%; median craniospinal irradiation dose was 30.6 Gy (relative biological effectiveness [RBE]), median total dose was 54.0 Gy (RBE), 80% received proton radiotherapy; 81% received chemotherapy. 5 year PFS and OS were 86.5% and 95.8%, respectively; 10 year PFS and OS were 83.9% and 90.7%, respectively. Anaplastic histology was associated with worse PFS (P = .04). Among eight recurrences, 25% presented after 5 years. Most common grade ≥2 late toxicities were anxiety/depressive symptoms (30%), motor dysfunction (25%), and ototoxicity (22%). Higher posterior fossa radiation dose was associated with increased risk of late toxicity, including worse cognitive dysfunction (P = .05). Conclusions Adults with MB have favorable survival outcomes, but late failures and toxicity are not uncommon. Better understanding of prognostic factors, possibly from molecular subtyping, may help to define more personalized treatments for patients with high risk of recurrence and long-term treatment sequelae.
- Published
- 2022
7. Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial
- Author
-
Anurag, Saraf, Luke R G, Pike, Kevin H, Franck, Nora K, Horick, Beow Y, Yeap, Barbara C, Fullerton, Irene S, Wang, Mohamed E, Abazeed, Michael J, McKenna, William A, Mehan, Scott R, Plotkin, Jay S, Loeffler, and Helen A, Shih
- Subjects
Adult ,Treatment Outcome ,Hearing ,Humans ,Surgery ,Neuroma, Acoustic ,Prospective Studies ,Neurology (clinical) ,Protons ,Hearing Loss ,Radiosurgery ,Follow-Up Studies ,Retrospective Studies - Abstract
Local management for vestibular schwannoma (VS) is associated with excellent local control with focus on preserving long-term serviceable hearing. Fractionated proton radiation therapy (FPRT) may be associated with greater hearing preservation because of unique dosimetric properties of proton radiotherapy.To investigate hearing preservation rates of FPRT in adults with VS and secondarily assess local control and treatment-related toxicity.A prospective, single-arm, phase 2 clinical trial was conducted of patients with VS from 2010 to 2019. All patients had serviceable hearing at baseline and received FPRT to a total dose of 50.4 to 54 Gy relative biological effectiveness (RBE) over 28 to 30 fractions. Serviceable hearing preservation was defined as a Gardner-Robertson score of 1 to 2, measured by a pure tone average (PTA) of ≤50 dB and a word recognition score (WRS) of ≥50%.Twenty patients had a median follow-up of 4.0 years (range 1.0-5.0 years). Local control at 4 years was 100%. Serviceable hearing preservation at 1 year was 53% (95% CI 29%-76%), and primary end point was not yet reached. Median PTA and median WRS both worsened 1 year after FPRT (P.0001). WRS plateaued after 6 months, whereas PTA continued to worsen up to 1 year after FPRT. Median cochlea D90 was lower in patients with serviceable hearing at 1 year (40.6 Gy [RBE] vs 46.9 Gy [RBE]), trending toward Wilcoxon rank-sum test statistical significance (P = .0863). Treatment was well-tolerated, with one grade 1 cranial nerve V dysfunction and no grade 2+ cranial nerve dysfunction.FPRT for VS did not meet the goal of serviceable hearing preservation. Higher cochlea doses trended to worsening hearing preservation, suggesting that dose to cochlea correlates with hearing preservation independent of treatment modality.
- Published
- 2022
8. Novel Mechanisms and Future Opportunities for the Management of Radiation Necrosis in Patients Treated for Brain Metastases in the Era of Immunotherapy
- Author
-
Eugene J. Vaios, Sebastian F. Winter, Helen A. Shih, Jorg Dietrich, Katherine B. Peters, Scott R. Floyd, John P. Kirkpatrick, and Zachary J. Reitman
- Subjects
Cancer Research ,Oncology - Abstract
Radiation necrosis, also known as treatment-induced necrosis, has emerged as an important adverse effect following stereotactic radiotherapy (SRS) for brain metastases. The improved survival of patients with brain metastases and increased use of combined systemic therapy and SRS have contributed to a growing incidence of necrosis. The cyclic GMP-AMP (cGAMP) synthase (cGAS) and stimulator of interferon genes (STING) pathway (cGAS-STING) represents a key biological mechanism linking radiation-induced DNA damage to pro-inflammatory effects and innate immunity. By recognizing cytosolic double-stranded DNA, cGAS induces a signaling cascade that results in the upregulation of type 1 interferons and dendritic cell activation. This pathway could play a key role in the pathogenesis of necrosis and provides attractive targets for therapeutic development. Immunotherapy and other novel systemic agents may potentiate activation of cGAS-STING signaling following radiotherapy and increase necrosis risk. Advancements in dosimetric strategies, novel imaging modalities, artificial intelligence, and circulating biomarkers could improve the management of necrosis. This review provides new insights into the pathophysiology of necrosis and synthesizes our current understanding regarding the diagnosis, risk factors, and management options of necrosis while highlighting novel avenues for discovery.
- Published
- 2023
9. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations
- Author
-
Anita Giobbie-Hurder, Tracy T. Batchelor, Maura Mahar, Michael White, Daniel P. Cahill, Rebecca S. Heist, Justine V. Cohen, Justin F. Gainor, Helen A. Shih, Priscilla K. Brastianos, Scott L. Carter, Ryan J. Sullivan, Deborah Forst, Donald P. Lawrence, Nancy Wang, David P. Ryan, Kevin S. Oh, Sandro Santagata, A. John Iafrate, Albert E. Kim, Jennifer A. Ligibel, Ugonma Chukwueke, Elizabeth R. Gerstner, and Eudocia Q. Lee
- Subjects
Cancer Research ,biology ,Kinase ,business.industry ,medicine.medical_treatment ,Palbociclib ,Interim analysis ,Targeted therapy ,Oncology ,Cyclin-dependent kinase ,Cancer research ,medicine ,Clinical endpoint ,biology.protein ,Metastatic brain cancer ,business ,CDK inhibitor - Abstract
Recent studies suggest that the cyclin-dependent kinase (CDK) pathway may be a therapeutic target for brain metastases (BM). Here, we present interim analysis of a basket trial evaluating the intracranial efficacy of the CDK inhibitor palbociclib in patients with progressive BM and CDK alterations. Our study met its primary endpoint and provides evidence for performing molecular testing of archival BM tissue, if available, to inform the choice of CNS-penetrant targeted therapy. Brastianos and colleagues report interim trial results on the intracranial clinical benefit of palbociclib for patients with progressive metastatic brain cancer carrying cyclin-dependent kinase pathway alterations.
- Published
- 2021
10. Modelling of late side-effects following cranial proton beam therapy
- Author
-
Steffen Löck, Beate Timmermann, Almut Dutz, Armin Lühr, M.R. Bussiere, Helen A. Shih, Xavier Vermeren, Mechthild Krause, Dirk Geismar, Michael H. Baumann, L. Agolli, Chiara Valentini, Emily S. Lebow, Esther G.C. Troost, Jillian E. Daly, Nayan Lamba, Rebecca Bütof, and Marc R. Bussière
- Subjects
Mild hearing impairment ,medicine.medical_specialty ,Medizin ,Estimating equations ,Logistic regression ,030218 nuclear medicine & medical imaging ,Cohort Studies ,Optic neuropathy ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Proton Therapy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Probability ,Receiver operating characteristic ,Brain Neoplasms ,business.industry ,Hematology ,medicine.disease ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Quality of Life ,Radiology ,Complication ,business - Abstract
Background The limited availability of proton beam therapy (PBT) requires individual treatment selection strategies that can be based on normal tissue complication probability (NTCP) models. We developed and externally validated NTCP models for common late side-effects following PBT in brain tumour patients to optimise patients’ quality of life. Methods Cohorts from three PBT centres (216 patients) were investigated for several physician-rated endpoints at 12 and 24 months after PBT: alopecia, dry eye syndrome, fatigue, headache, hearing and memory impairment, and optic neuropathy. Dose-volume parameters of associated normal tissues and clinical factors were used for logistic regression modelling in a development cohort. Statistically significant parameters showing high area under the receiver operating characteristic curve (AUC) values in internal cross-validation were externally validated. In addition, analyses of the pooled cohorts and of time-dependent generalised estimating equations including all patient data were performed. Results In the validation study, mild alopecia was related to high dose parameters to the skin [e.g. the dose to 2% of the volume (D2%)] at 12 and 24 months after PBT. Mild hearing impairment at 24 months after PBT was associated with the mean dose to the ipsilateral cochlea. Additionally, the pooled analyses revealed dose–response relations between memory impairment and intermediate to high doses to the remaining brain as well as D2% of the hippocampi. Mild fatigue at 24 months after PBT was associated with D2% to the brainstem as well as with concurrent chemotherapy. Moreover, in generalised estimating equations analysis, dry eye syndrome was associated with the mean dose to the ipsilateral lacrimal gland. Conclusion We developed and in part validated NTCP models for several common late side-effects following PBT in brain tumour patients. Validation studies are required for further confirmation.
- Published
- 2021
11. Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas
- Author
-
Nayan Lamba, Helen A. Shih, Grace M. Lee, Daniel Kim, Andrzej Niemierko, Robert L. Martuza, Fred G. Barker, Jay S. Loeffler, Paul H. Chapman, Kevin S. Oh, and William T. Curry
- Subjects
Surgical resection ,Cancer Research ,medicine.medical_specialty ,Adjuvant radiotherapy ,Radiation ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Lower risk ,Gastroenterology ,Confidence interval ,030218 nuclear medicine & medical imaging ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Tumor progression ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,business ,Adjuvant - Abstract
PURPOSE The optimal timing of adjuvant radiation therapy (RT) in the management of atypical meningiomas remains controversial. We compared the outcomes of atypical meningiomas managed with upfront adjuvant RT versus postoperative surveillance. METHODS AND MATERIALS Patients with intracranial atypical meningiomas who underwent resection between 2000 and 2015 at a single institution were identified. Patients receiving adjuvant RT (n = 51), defined as RT within the first year of surgery before tumor progression/recurrence (P/R), were compared with those undergoing initial surveillance (n = 179). The primary endpoints were radiographic evidence of P/R and time to P/R from surgery. RESULTS A total of 230 patients were identified. Fifty-one (22%) patients received upfront adjuvant RT, and 179 (78%) underwent surveillance. Compared with the surveillance group, patients who received adjuvant RT had larger tumors (5.2 cm vs 4.6 cm; P = .04), were more likely to have undergone subtotal resection (65% vs 26%; P < . 01), and more often had bone invasion (18% vs 7%; P = .02). On multivariable analysis, receipt of adjuvant RT was associated with a lower risk of P/R compared with surveillance (hazard ratio, 0.21; 95% confidence interval, 0.11-0.41; P < .01). Patients who initially underwent surveillance and then received salvage RT at time of P/R had a shorter median time to local progression after RT compared with patients who developed local P/R after upfront adjuvant RT (19 vs 64 months, respectively; P < . 01). CONCLUSION Upfront adjuvant RT was associated with improved local control in atypical meningiomas irrespective of extent of initial resection compared with surveillance. Early adjuvant RT should be strongly considered after gross total resection of atypical meningiomas.
- Published
- 2021
12. Brain Necrosis in Adult Patients After Proton Therapy: Is There Evidence for Dependency on Linear Energy Transfer?
- Author
-
Genevieve Maquilan, Jan Schuemann, Andrzej Niemierko, Harald Paganetti, Drosoula Giantsoudi, Helen A. Shih, and Maximilian Niyazi
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Endpoint Determination ,medicine.medical_treatment ,Linear energy transfer ,computer.software_genre ,Article ,030218 nuclear medicine & medical imaging ,Necrosis ,03 medical and health sciences ,0302 clinical medicine ,Voxel ,Proton Therapy ,medicine ,Relative biological effectiveness ,Humans ,Linear Energy Transfer ,Radiology, Nuclear Medicine and imaging ,Radiosensitivity ,Proton therapy ,Retrospective Studies ,Radiation ,medicine.diagnostic_test ,business.industry ,Head and neck cancer ,Brain ,Radiotherapy Dosage ,Magnetic resonance imaging ,medicine.disease ,Radiation therapy ,Oncology ,030220 oncology & carcinogenesis ,Female ,Radiology ,business ,computer - Abstract
Purpose To investigate if radiographic imaging changes defined as necrosis correlate with regions in the brain with elevated linear energy transfer (LET) for proton radiation therapy treatments with partial brain involvement in central nervous system and patients with head and neck cancer. Methods and Materials Fifty patients with head and neck, skull base, or intracranial tumors who underwent proton therapy between 2004 to 2016 with a minimum prescription dose of 59.4 Gy (relative biological effectiveness) and with magnetic resonance imaging changes indicative of brain necrosis after radiation therapy were retrospectively reviewed. Each treatment plan was recalculated using Monte Carlo simulations to provide accurate dose distributions as well as 3-dimensional distributions of LET. To assess the effect of LET on radiographic imaging changes several voxel-based analyses were performed. Results In this patient cohort, LET adjusted for dose was not found to be associated with risk of brain necrosis. Conclusions A voxel-based analysis of brain necrosis as an endpoint is difficult owing to uncertainties in the origin of necrosis, timing of imaging, variability in patient specific radiosensitivity, and the simultaneous effect of dose and LET. Even though it is expected that the LET and thus relative biological effectiveness increases at the end of range, effects in patients might be small compared with interpatient variability of radiosensitivity and might be obscured by other confounding factors.
- Published
- 2021
13. Protons or Photons – Let's Get It Done
- Author
-
Felix Ehret and Helen A. Shih
- Subjects
Cancer Research ,Radiation ,Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2023
14. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient
- Author
-
Daniel N. Cagney, Shane Mesko, Diana D. Shi, Emil Lou, John Bryant, Supriya K. Jain, Hany Soliman, Arjun Sahgal, John P. Kirkpatrick, Eric Nesbit, Kristin A. Plichta, Cheng-Chia Wu, Steve Braunstein, Ashlyn S. Everett, Laurie E. Gaspar, Ryan Shanley, Drexell Hunter Boggs, Laura Masucci, Yi An, Jessica W. Lee, Ayal A. Aizer, Jing Li, William Sperduto, Paul D. Brown, Minesh P. Mehta, William G. Breen, Tim J. Kruser, Toshimichi Nakano, Hidefumi Aoyama, Veronica Chiang, Jill Remick, Paul W. Sperduto, John M. Buatti, Nan Lin, Tony J. C. Wang, Michael D. Chuong, Jason Chan, David Roberge, and Helen A. Shih
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Clinical Sciences ,Oncology and Carcinogenesis ,MEDLINE ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Neoplasms ,Internal medicine ,Original Reports ,80 and over ,medicine ,Humans ,In patient ,Oncology & Carcinogenesis ,Karnofsky Performance Status ,Precision Medicine ,Cancer ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,screening and diagnosis ,Brain Neoplasms ,business.industry ,Proportional hazards model ,Middle Aged ,Prognosis ,Precision medicine ,Brain Disorders ,Brain Cancer ,Clinical trial ,Detection ,030104 developmental biology ,Multicenter study ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Female ,Neoplasm Grading ,business ,4.2 Evaluation of markers and technologies - Abstract
PURPOSE Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility. METHODS A multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively. RESULTS Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation ( P < .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively. CONCLUSION Median survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient > 0.50).
- Published
- 2020
15. A Systematic Comparison of Dose Distributions Delivered in
- Author
-
Alexei V, Trofimov, Mary E, Aronow, Evangelos S, Gragoudas, Florence K, Keane, Ivana K, Kim, Helen A, Shih, and Mandar S, Bhagwat
- Abstract
To characterize dose distributions withPlaque and proton treatment plans were created for 4 groups of cases: (1) REF: 39 instances of reference midsize circular-base tumor (d = 12 mm, h = 5 mm), in locations varying by retinal clock hours and distance to fovea, optic disc, and corneal limbus; (2) SUP: 25 superiorly located; (3) TEMP: 25 temporal; and (4) NAS: 25 nasally located tumors that were a fixed distance from the fovea but varying in d (6-18 mm) and h (3-11 mm). For both modalities, 111 unique scenarios were characterized in terms of the distance to points of interest, doses delivered to fovea, optic disc, optic nerve at 3 mm posterior to the disc (ON@3mm), lens, and retina. Comparative statistical evaluation was performed with the Mann-Whitney U test.Superior dose distributions favored plaque for sparing of (1) fovea in large (d + h ≥ 21 mm) NAS tumors; (2) ON@3mm in REF cases located ≤4 disc diameters from disc, and in NAS overall. Protons achieved superior dose sparing of (1) fovea and optic disc in REF, SUP, and TEMP; (2) ON@3mm in REF4 disc diameters from disc, and in SUP and TEMP; and (3) the lens center overall and lens periphery in REF ≤6 mm from the corneal limbus, and in TEMP with h = 3 mm. Although protons could completely spare sections of the retina, plaque dose was more target conformal in the high-dose range (50% and 90% of prescription dose).Although comparison between plaque and proton therapy is not straightforward because of the disparity in dose rate, prescriptions, applicators, and delivery techniques, it is possible to identify distinctions between dose distributions, which could help inform decisions by providers and patients.
- Published
- 2022
16. A Comparison of Treatment Outcomes after Standard Dose (70 Gy) versus Reduced Dose (50 Gy) Proton Radiation in Patients with Uveal Melanoma
- Author
-
Anne Marie Lane, Monica M. Oxenreiter, Mustafa Hashmi, Mary E. Aronow, Alexei V. Trofimov, Helen A. Shih, Evangelos S. Gragoudas, and Ivana K. Kim
- Subjects
Ophthalmology ,Treatment Outcome ,Humans ,Protons ,Neoplasm Recurrence, Local ,Melanoma ,Retrospective Studies - Abstract
To compare outcomes in a large patient cohort with small-medium tumors located within 1 disc diameter (DD) of the optic nerve and/or fovea treated with 50 Gy or 70 Gy proton therapy.Retrospective cohort study.A total of 1120 patients with uveal melanomas ≤ 15 mm in largest basal diameter, ≤ 5 mm in height, located within 1 DD of the optic nerve and/or fovea, who received primary treatment with protons between 1975 and 2016 at Massachusetts Eye and Ear/Massachusetts General Hospital.The rates of outcomes were estimated using the Kaplan-Meier method. Differences between the radiation dose groups were tested using the log-rank test.Local tumor recurrence, melanoma-related mortality, and visual acuity preservation (≥ 20/200, ≥ 20/40).Local tumor recurrence was observed in 1.8% of the 50 Gy group and 1.5% of the 70 Gy group. The median time to recurrence was 30.7 months for patients treated with 50 Gy and 32.0 months for those treated with 70 Gy (P = 0.28). Five-year rates of vision retention (≥20/40, ≥ 20/200) were 19.4% and 49.3% for patients treated with 50 Gy and 16.4% and 40.7% in those treated with 70 Gy. Ten-year rates of melanoma-related mortality were 8.4% in the 50 Gy group and 8.9% in the 70 Gy group (P = 0.47).Comparable rates of local control are achieved treating small-medium tumors near the optic nerve and/or fovea with 50 Gy or 70 Gy proton therapy, supporting the use of the lower dose in patients with these tumor characteristics.
- Published
- 2022
17. Proton Beam Irradiation: Expanding Indications
- Author
-
Mary E. Aronow, Alexei V. Trofimov, Anne Marie Lane, Yen-Lin E. Chen, Florence K. Keane, Shannon M. MacDonald, Helen A. Shih, Evangelos S. Gragoudas, and Ivana K. Kim
- Published
- 2022
18. Clinical Presentation and Management of SMART Syndrome
- Author
-
Eugene J Vaios, Jorg Dietrich, Eudocia Q. Lee, Helen A. Shih, Franziska Loebel, Joshua P. Klein, Philipp Karschnia, and Sebastian F Winter
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,technology, industry, and agriculture ,Treatment options ,medicine.disease ,Cranial radiation ,humanities ,Radiation therapy ,Text mining ,Migraine ,Tumor progression ,medicine ,Neurology (clinical) ,Radiology ,Headaches ,medicine.symptom ,Presentation (obstetrics) ,business - Abstract
Stroke-like migraine attacks after radiation therapy (SMART) syndrome represents a rare but serious condition manifesting years after cranial radiation therapy (RT).1 Characterized by migraine-type headaches, stroke-like deficits, seizures, and MRI abnormalities, including cortical gyriform enhancement in irradiated brain regions, SMART is diagnostically and therapeutically challenging.2-6 Distinction from tumor progression is difficult and treatment options are limited.2 Although frequently reversible,5 SMART episodes can recur6 and effectuate persistent neurologic or imaging sequelae.3
- Published
- 2021
19. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons
- Author
-
Caroline Chung, Susan L. McGovern, Clemens Grassberger, Paul D. Brown, Mary Frances McAleer, David R. Grosshans, Anita Mahajan, Amy B. Heimberger, Amol J. Ghia, Steven H. Lin, Cong Zhu, Jeffrey Dinh, Amy Liu, John de Groot, Jing Li, Radhe Mohan, Sarah McAvoy, Susannah G. Ellsworth, Helen A. Shih, and Erik P. Sulman
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Clinical Investigations ,Urology ,Logistic regression ,Lymphopenia ,Proton Therapy ,medicine ,Relative biological effectiveness ,Humans ,Photons ,Temozolomide ,Receiver operating characteristic ,Brain Neoplasms ,business.industry ,Area under the curve ,Odds ratio ,Confidence interval ,Radiation therapy ,Oncology ,Neurology (clinical) ,Protons ,Glioblastoma ,business ,medicine.drug - Abstract
Background We investigated differences in radiation-induced grade 3+ lymphopenia (G3+L), defined as an absolute lymphocyte count (ALC) nadir of Methods Patients enrolled in a randomized phase II trial received PT (n = 28) or XRT (n = 56) concomitantly with temozolomide. ALC was measured before, weekly during, and within 1 month after radiotherapy. Whole-brain mean dose (WBMD) and brain dose-volume indices were extracted from planned dose distributions. Univariate and multivariate logistic regression analyses were used to identify independent predictive variables. The resulting model was evaluated using receiver operating characteristic (ROC) curve analysis. Results Rates of G3+L were lower in men (7/47 [15%]) versus women (19/37 [51%]) (P < 0.001), and for PT (4/28 [14%]) versus XRT (22/56 [39%]) (P = 0.024). G3+L was significantly associated with baseline ALC, WBMD, and brain volumes receiving 5‒40 Gy(relative biological effectiveness [RBE]) or higher (ie, V5 through V40). Stepwise multivariate logistic regression analysis identified being female (odds ratio [OR] 6.2, 95% confidence interval [CI]: 1.95‒22.4, P = 0.003), baseline ALC (OR 0.18, 95% CI: 0.05‒0.51, P = 0.003), and whole-brain V20 (OR 1.07, 95% CI: 1.03‒1.13, P = 0.002) as the strongest predictors. ROC analysis yielded an area under the curve of 0.86 (95% CI: 0.79–0.94) for the final G3+L prediction model. Conclusions Sex, baseline ALC, and whole-brain V20 were the strongest predictors of G3+L for patients with GBM treated with radiation and temozolomide. PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.
- Published
- 2020
20. Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma
- Author
-
Daniel M. Trifiletti, Timothy D. Malouff, Helen A. Shih, Daniel P. Cahill, Susan L. McGovern, Andrew B. Lassman, Paul D. Brown, Shiao Pei Weathers, and Tony J. C. Wang
- Subjects
Oncology ,Hypofractionated Radiotherapy ,Cancer Research ,medicine.medical_specialty ,As Directed ,Astrocytoma ,Recurrent Glioma ,Systemic therapy ,Re-Irradiation ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Repeat analysis ,Brain Neoplasms ,Practice patterns ,business.industry ,Subtotal Resection ,Chemoradiotherapy ,medicine.disease ,Combined Modality Therapy ,030220 oncology & carcinogenesis ,Dose Fractionation, Radiation ,Neoplasm Recurrence, Local ,business ,Anaplastic astrocytoma - Abstract
Treatment of recurrent gliomas is especially challenging, as many of these patients have previously been treated with extensive surgery, radiation, or systemic therapy. Due to this, the optimum therapy for patients with recurrent glioma is controversial, with widely variable practice patterns. In this opinion piece, a multidisciplinary panel of experts provides rationale for their treatment approach in a patient with recurrent glioma following subtotal resection with adjuvant chemoradiation for an anaplastic astrocytoma. In summary, the consensus of the panel was to recommend re-resection if possible with hypofractionated radiotherapy schedules, with re-irradiation and systemic therapy as directed by a multidisciplinary team through repeat analysis of the tumor specimen for an updated mutational burden.
- Published
- 2020
21. ACR–ASTRO Practice Parameter for Communication
- Author
-
Alan C. Hartford, J B Wilkinson, Malcolm D. Mattes, Michael M. Dominello, Jeff M. Michalski, Joseph Bovi, Helen A. Shih, Derek Brown, Eric A. Strom, Arthur K Liu, Naomi R. Schechter, and Seth A. Rosenthal
- Subjects
Physician-Patient Relations ,Cancer Research ,medicine.medical_specialty ,business.industry ,Communication ,Medical record ,medicine.medical_treatment ,Technical standard ,Referring Physician ,Medical Records ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,Documentation ,Oncology ,Multidisciplinary approach ,030220 oncology & carcinogenesis ,Health care ,Radiation Oncology ,medicine ,Humans ,Medical physics ,030212 general & internal medicine ,business ,Radiation oncologist - Abstract
Aim/objectives/background Timely, accurate, and effective communications are critical to quality in contemporary medical practices. Radiation oncology incorporates the science and technology of complex integrated radiation treatment delivery and the art of managing individual patients. Through written physical and/or electronic reports and direct communication, radiation oncologists convey critical information regarding patient care, services provided, and quality of care. Applicable practice parameters need to be revised periodically regarding medical record documentation for professional and technical components of services delivered. Methods The ACR-ASTRO Practice Parameter for Communication: Radiation Oncology was revised according to the process described on the American College of Radiology (ACR) Web site ("The Process for Developing ACR Practice Parameters and Technical Standards," www.acr.org/ClinicalResources/Practice-Parametersand-Technical-Standards) by the Committee on Practice Parameters of the ACR Commission on Radiation Oncology in collaboration with the American Society for Radiation Oncology (ASTRO). Both societies then reviewed and approved the document. Results This practice parameter addresses radiation oncology communications in general, including (a) medical record, (b) electronic, and (c) doctor-patient communications, as well as specific documentation for radiation oncology reports such as (a) consultation, (b) clinical treatment management notes (including inpatient communication), (c) treatment (completion) summary, and (d) follow-up visits. Conclusions The radiation oncologist's participation in the multidisciplinary management of patients is reflected in timely, medically appropriate, and informative communication with the referring physician and other members of the health care team. The ACR-ASTRO Practice Parameter for Communication: Radiation Oncology is an educational tool designed to assist practitioners in providing appropriate communication regarding radiation oncology care for patients.
- Published
- 2020
22. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
- Author
-
Daniel P. Cahill, Scott L. Carter, Nan Lin, Brian V. Nahed, Jorg Dietrich, Ugonma Chukwueke, Ian E. Krop, Christopher Alvarez-Breckenridge, Nancy Wang, Anita Giobbie-Hurder, Maura Mahar, Beverly Moy, Priscilla K. Brastianos, Justine V. Cohen, Mia Bertalan, Deborah Forst, Michael White, Tracy T. Batchelor, Sara M. Tolaney, Brian A. Shaw, Donald P. Lawrence, Lakshmi Nayak, Helen A. Shih, Kevin S. Oh, Nathaniel Goss, Naema Nayyar, Albert H. Kim, Ryan J. Sullivan, Elizabeth R. Gerstner, Megha Subramanian, Joana L. Mora, and Eudocia Q. Lee
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Lung Neoplasms ,Vomiting ,Nausea ,Phases of clinical research ,Breast Neoplasms ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,Disease-Free Survival ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Internal medicine ,Clinical endpoint ,Humans ,Medicine ,Neoplasm Metastasis ,Lung cancer ,Adverse effect ,Ovarian Neoplasms ,Dose-Response Relationship, Drug ,business.industry ,General Medicine ,medicine.disease ,Clinical trial ,030104 developmental biology ,Hyperglycemia ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,business ,Meningeal Carcinomatosis - Abstract
An increasing fraction of patients with metastatic cancer develop leptomeningeal dissemination of disease (LMD), and survival is dismal1–3. We conducted a single-arm, phase 2 study of pembrolizumab in patients with solid tumor malignancies and LMD (NCT02886585). Patients received 200 mg of pembrolizumab intravenously every 3 weeks until definitive progression or unacceptable toxicity. The primary endpoint was rate of overall survival at 3 months (OS3). Secondary objectives included toxicity, response rate and time to intracranial or extracranial disease progression. A Simon two-stage design was used to compare a null hypothesis OS3 of 18% against an alternative of 43%. Twenty patients—17 with breast cancer, two with lung cancer and one with ovarian cancer—were enrolled into the pre-specified evaluation group having received at least one dose of pembrolizumab. The median follow-up of surviving patients was 6.3 months (range, 2.2–12.5 months). The percentage of patients who experienced one (or more) grade 3 or higher adverse events at least possibly related to treatment was 40%, the most frequent being hyperglycemia (n = 6), nausea (n = 7) and vomiting (n = 7). The study met the primary endpoint, as 12 of 20 (OS3, 0.60; 90% confidence interval, 0.39–0.78) patients were alive at 3 months after enrollment. Pembrolizumab is safe and feasible and displays promising activity in patients with LMD. Further investigations are needed to identify which patients with LMD can benefit from pembrolizumab. In a phase 2 clinical trial cohort of patients with leptomeningeal disease, anti-PD-1 monotherapy was safe and associated with a 3-month overall survival of 60%.
- Published
- 2020
23. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today
- Author
-
Ashlyn S. Everett, Emil Lou, Drexell Hunter Boggs, Helen A. Shih, Jessica W. Lee, Laura Masucci, Diana D. Shi, Jason Chan, Paul W. Sperduto, Laurie E. Gaspar, Paul D. Brown, Minesh P. Mehta, Jing Li, William Sperduto, Jill Remick, David Roberge, John M. Buatti, Nan Lin, Shane Mesko, Ryan Shanley, Kristin A. Plichta, Tony J. C. Wang, William G. Breen, John P. Kirkpatrick, Arjun Sahgal, Toshimichi Nakano, Ayal A. Aizer, James B. Yu, Michael D. Chuong, Supriya K. Jain, Hany Soliman, Veronica Chiang, John Bryant, Daniel N. Cagney, Hidefumi Aoyama, Cheng-Chia Wu, Tim J. Kruser, Steve Braunstein, and Eric Nesbit
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Clinical Sciences ,Oncology and Carcinogenesis ,Breast Neoplasms ,Article ,030218 nuclear medicine & medical imaging ,Retrospective database ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Breast cancer ,Clinical Research ,Internal medicine ,Breast Cancer ,80 and over ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Oncology & Carcinogenesis ,Survival analysis ,Cancer ,Aged ,Retrospective Studies ,Aged, 80 and over ,Radiation ,BRCA1 Protein ,Brain Neoplasms ,business.industry ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Other Physical Sciences ,Clinical trial ,Tumor Subtype ,030220 oncology & carcinogenesis ,Cohort ,Female ,business ,Median survival - Abstract
PurposeBrain metastases are a common sequelae of breast cancer. Survival varies widely based on diagnosis-specific prognostic factors (PF). We previously published a prognostic index (Graded Prognostic Assessment [GPA]) for patients with breast cancer with brain metastases (BCBM), based on cohort A (1985-2007, n = 642), then updated it, reporting the effect of tumor subtype in cohort B (1993-2010, n = 400). The purpose of this study is to update the Breast GPA with a larger contemporary cohort (C) and compare treatment and survival across the 3 cohorts.Methods and materialsA multi-institutional (19), multinational (3), retrospective database of 2473 patients with breast cancer with newly diagnosed brain metastases (BCBM) diagnosed from January 1, 2006, to December 31, 2017, was created and compared with prior cohorts. Associations of PF and treatment with survival were analyzed. Kaplan-Meier survival estimates were compared with log-rank tests. PF were weighted and the Breast GPA was updated such that a GPA of 0 and 4.0 correlate with the worst and best prognoses, respectively.ResultsMedian survival (MS) for cohorts A, B, and C improved over time (from 11, to 14 to 16 months, respectively; P < .01), despite the subtype distribution becoming less favorable. PF significant for survival were tumor subtype, Karnofsky Performance Status, age, number of BCBMs, and extracranial metastases (all P < .01). MS for GPA 0 to 1.0, 1.5-2.0, 2.5-3.0, and 3.5-4.0 was 6, 13, 24, and 36 months, respectively. Between cohorts B and C, the proportion of human epidermal receptor 2 + subtype decreased from 31% to 18% (P < .01) and MS in this subtype increased from 18 to 25 months (P < .01).ConclusionsMS has improved modestly but varies widely by diagnosis-specific PF. New PF are identified and incorporated into an updated Breast GPA (free online calculator available at brainmetgpa.com). The Breast GPA facilitates clinical decision-making and will be useful for stratification of future clinical trials. Furthermore, these data suggest human epidermal receptor 2-targeted therapies improve clinical outcomes in some patients with BCBM.
- Published
- 2020
24. Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases
- Author
-
Stephen Zieminski, Helen A. Shih, William A. Mehan, Henning Willers, Yi Wang, Emily S. Lebow, Melin J. Khandekar, William L. Hwang, Kevin S. Oh, and Andrzej Niemierko
- Subjects
Male ,Oncology ,Simultaneous integrated boost ,Cancer Research ,medicine.medical_specialty ,Neurology ,Nausea ,Kaplan-Meier Estimate ,Hippocampal formation ,Hippocampus ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Parenchyma ,medicine ,Humans ,Cognitive decline ,Radiation Injuries ,Aged ,Brain Neoplasms ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Middle Aged ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Neurology (clinical) ,Cranial Irradiation ,medicine.symptom ,Stem cell ,business ,Whole brain radiation therapy ,030217 neurology & neurosurgery - Abstract
Cranial irradiation results in cognitive decline, which is hypothesized to be partially attributable to hippocampal injury and stem cell loss. Recent advances allow for targeted reduction of radiation dose to the hippocampi while maintaining adequate dose coverage to the brain parenchyma and additional increasing dose to brain metastases, a approach called hippocampal avoidance whole brain radiation therapy with a simultaneous integrated boost (HA-WBRT + SIB.) We review our early clinical experience with HA-WBRT + SIB. We evaluated treatments and clinical outcomes for patients treated with HA-WBRT + SIB between 2014 and 2018. A total of 32 patients (median age, 63.5 years, range 45.3–78.8 years) completed HA-WBRT + SIB. Median follow-up for patients alive at the time of analysis was 11.3 months. The most common histology was non-small cell lung cancer (n = 22). Most patients (n = 25) were prescribed with WBRT dose of 30 Gy with SIB to 37.5 Gy in 15 fractions. Volumetric modulated arc therapy reduced treatment time (p
- Published
- 2020
25. The Interaction of Waiting Time and Patient Experience during Radiation Therapy: A Survey of Patients from a Tertiary Cancer Center
- Author
-
Helen A. Shih, Peggy Leland, Andrzej Niemierko, Nayan Lamba, and Ruben Martinez
- Subjects
Male ,Waiting time ,medicine.medical_specialty ,Waiting Lists ,medicine.medical_treatment ,Anxiety ,030218 nuclear medicine & medical imaging ,Tertiary Care Centers ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Emotional distress ,Surveys and Questionnaires ,Patient experience ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Aged ,Pain Measurement ,Travel ,Radiotherapy ,Radiological and Ultrasound Technology ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Tumor site ,Radiation therapy ,Patient Satisfaction ,030220 oncology & carcinogenesis ,Physical therapy ,Female ,medicine.symptom ,business - Abstract
Purpose The logistical burdens of appointment scheduling and travel add to the psychological and emotional distress among patients with a new cancer diagnosis. This may be heightened among patients needing radiation therapy (RT), who must travel to and from a treatment facility daily for several weeks. Here, we studied the association between RT appointment waiting time and patient-reported pain and anxiety and explored additional factors that may influence daily waiting time. Methods Ninety-four patients undergoing RT at a single, academic institution were surveyed in the first and final weeks of treatment. On the day of the survey, patients were asked to report: pain (Likert scale: 0–10), anxiety (0–10), commute mode/time, and estimated waiting time for RT. Actual waiting times were calculated per review of the electronic scheduling system. Results Increased objective waiting time was associated with higher pain scores at the start (P = .05) and end (P = 0.004) of RT, although overall pain scores were low at both time points (mean 1.4 and 1.5, respectively). Anxiety scores were also low (mean 1.2 at both time points) and were not associated with objective waiting time (P > .05). Of note, patients reported perceived waiting times that were considerably shorter than actual waiting times (mean 15 vs. 26 minutes, respectively, at first survey early in the RT course). Time of day and tumor site were not associated with waiting time. Conclusion Daily waiting time may play a role in pain and/or anxiety experienced by patients with cancer during RT. Perceived waiting time may differ substantially from actual waiting time and represents a potential area for intervention to improve patients’ quality of life.
- Published
- 2020
26. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
- Author
-
David Roberge, Jing Li, Steve Braunstein, Drexell Hunter Boggs, Laurie E. Gaspar, Emil Lou, Supriya K. Jain, Jessica W. Lee, Hany Soliman, Laura Masucci, Jill Remick, Arjun Sahgal, John P. Kirkpatrick, William Sperduto, William G. Breen, Jason Chan, Toshimichi Nakano, Diana D. Shi, Paul D. Brown, James B. Yu, Minesh P. Mehta, Helen A. Shih, Veronica Chiang, Paul W. Sperduto, John M. Buatti, Daniel N. Cagney, Kristin A. Plichta, Nan Lin, Michael D. Chuong, Tim J. Kruser, Eric Nesbit, Ashlyn S. Everett, Ryan Shanley, Shane Mesko, Cheng-Chia Wu, Ayal A. Aizer, Hidefumi Aoyama, John Bryant, and Tony J. C. Wang
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Receptor Status ,Receptor, ErbB-2 ,medicine.drug_class ,Clinical Trials and Supportive Activities ,Oncology and Carcinogenesis ,Clinical Investigations ,Estrogen receptor ,Breast Neoplasms ,Metastasis ,breast cancer ,ErbB-2 ,Breast cancer ,Clinical Research ,brain metastases ,Internal medicine ,Receptors ,Biomarkers, Tumor ,2.1 Biological and endogenous factors ,Humans ,Medicine ,Oncology & Carcinogenesis ,Aetiology ,Receptor ,Progesterone ,Cancer ,Retrospective Studies ,Tumor ,Brain Neoplasms ,business.industry ,Neurosciences ,Estrogens ,medicine.disease ,Primary tumor ,Good Health and Well Being ,Estrogen ,Hormone receptor ,estrogen/progesterone/HER2 receptor discordance ,Neurology (clinical) ,Receptors, Progesterone ,business ,Biomarkers - Abstract
Background Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM). Methods A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM. Results The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors—nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17–28 mo, P = 0.12; HER2, 15–19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27–18 mo, P = 0.02; HER2, 30–18 mo, P = 0.08). Conclusions Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly. Key Points 1. Receptor discordance alters subtype in 32% of BCBM patients. 2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively. 3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment.
- Published
- 2020
27. Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis
- Author
-
Marc D. Benayoun, Andrzej Niemierko, Wenya Linda Bi, Helen A. Shih, Kevin S. Oh, William A. Mehan, Jay S. Loeffler, Daniel Kim, Robert L. Martuza, Fred G. Barker, William L. Hwang, Elizabeth B. Claus, Ian F. Dunn, Ayal A. Aizer, William T. Curry, Nayan Lamba, Brian M. Alexander, and Ariel E. Marciscano
- Subjects
Male ,medicine.medical_specialty ,Histopathological grading ,Prominent nucleoli ,Gastroenterology ,Treatment failure ,World health ,Meningioma ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Meningeal Neoplasms ,medicine ,Atypia ,Humans ,Treatment Failure ,Retrospective Studies ,Univariate analysis ,business.industry ,Prognosis ,medicine.disease ,Confidence interval ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,Radiotherapy, Adjuvant ,Surgery ,Neurology (clinical) ,Neoplasm Grading ,business ,030217 neurology & neurosurgery - Abstract
Histopathological grading of meningiomas is insufficient for optimal risk stratification. The purpose of the present study was to determine the prognostic value of atypical histopathological features across all nonmalignant meningiomas (World Health Organization [WHO] grade I-II).The data from 334 patients with WHO grade I (n = 275) and grade II (n = 59) meningiomas who had undergone surgical resection from 2001 to 2015 at 2 academic centers were pooled. Progression/recurrence (P/R) was determined radiographically and measured from the date of surgery.The median follow-up was 52 months. The patients were stratified by the number of atypical features: 0 (n = 151), 1 (n = 71), 2 (n = 66), 3 (n = 22), and 4 or 5 (n = 24). The risk of P/R increased with an increasing number of atypical features (log-rank test, P = 0.001). The 5-year actuarial rates of P/R stratified by the number of atypical features were as follows: 0, 16.3% (95% confidence interval [CI], 10.7-24.4); 1, 21.7% (95% CI, 12.8-35.2); 2, 28.2% (95% CI, 18.4-41.7); 3, 30.4% (95% CI, 13.8-58.7); and 4 or 5, 51.4% (95% CI, 31.7-74.5). On univariate analysis, the presence of high nuclear/cytoplasmic ratio (P = 0.007), prominent nucleoli (P = 0.007), and necrosis (P0.00005) were associated with an increased risk of P/R. On multivariate analysis, the number of atypical features (hazard ratio [HR], 1.30; 95% CI, 1.03-1.63; P = 0.03), ≥4 mitoses per high-power fields (HR, 2.45; 95% CI, 1.17-5.15; P = 0.02), subtotal resection (HR, 3.9; 95% CI, 2.5-6.3; P0.0005), and the lack of adjuvant radiotherapy (HR, 2.40; 95% CI, 1.19-4.80; P = 0.01) were associated with an increased risk of P/R.An increased number of atypical features, ≥4 mitoses per 10 high-power fields, subtotal resection, and the lack of adjuvant radiotherapy were independently associated with P/R of WHO grade I-II meningiomas. Patients with these features might benefit from intensified therapy.
- Published
- 2020
28. Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model
- Author
-
Matthias Söhn, Vince Kim, Claus Belka, Helen A. Shih, Paul M. Busse, Maximilian Niyazi, Harald Paganetti, Kevin S. Oh, Saveli Goldberg, William L. Hwang, Andrzej Niemierko, Hsiao-Ming Lu, Judith Adams, Emily Schapira, and Jay S. Loeffler
- Subjects
Adult ,Male ,medicine.medical_specialty ,Necrosis ,Adolescent ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Actuarial Analysis ,Proton Therapy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Proton therapy ,Aged ,Probability ,Retrospective Studies ,Aged, 80 and over ,Nasopharyngeal Carcinoma ,Brain Neoplasms ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Confounding ,Brain ,Nasopharyngeal Neoplasms ,Radiotherapy Dosage ,Hematology ,Middle Aged ,medicine.disease ,Primary tumor ,Radiation therapy ,Radiation necrosis ,Oncology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Female ,Dose Fractionation, Radiation ,Radiology ,medicine.symptom ,Complication ,business - Abstract
Background and purpose High-dose fractionated radiotherapy is often necessary to achieve long-term tumor control in several types of tumors involving or within close proximity to the brain. There is limited data to guide on optimal constraints to the adjacent nontarget brain. This investigation explored the significance of the three-dimensional (3D) dose distribution of passive scattering proton therapy to the brain with other clinicopathological factors on the development of symptomatic radiation necrosis. Materials and methods All patients with head and neck, skull base, or intracranial tumors who underwent proton therapy (minimum prescription dose of 59.4 Gy(RBE)) with collateral moderate to high dose radiation exposure to the nontarget brain were retrospectively reviewed. A mixture cure model with respect to necrosis-free survival was used to derive estimates for the normal tissue complication probability (NTCP) model while adjusting for potential confounding factors. Results Of 179 identified patients, 83 patients had intracranial tumors and 96 patients had primary extracranial tumors. The optimal dose measure obtained to describe the occurrence of radiation necrosis was the equivalent uniform dose (EUD) with parameter a = 9. The best-fit parameters of logistic NTCP models revealed D50 = 57.7 Gy for intracranial tumors, D50 = 39.5 Gy for extracranial tumors, and γ50 = 2.5 for both tumor locations. Multivariable analysis revealed EUD and primary tumor location to be the strongest predictors of brain radiation necrosis. Conclusion In the current clinical volumetric data analyses with multivariable modelling, EUD was identified as an independent and strong predictor for brain radiation necrosis from proton therapy.
- Published
- 2020
29. Clinical outcomes and toxicity of proton radiotherapy for vestibular schwannomas: a systematic review
- Author
-
Kimberley S. Koetsier, Erik F. Hensen, Helen A. Shih, Marco van Vulpen, I.M. Lips, Rudolf Wiggenraad, and Peter Paul G. van Benthem
- Subjects
medicine.medical_specialty ,Hearing loss ,medicine.medical_treatment ,Population ,Schwannoma ,03 medical and health sciences ,Vestibular schwannoma ,0302 clinical medicine ,Quality of life ,Surgical oncology ,otorhinolaryngologic diseases ,Medicine ,education ,Vestibular system ,education.field_of_study ,Radiotherapy ,business.industry ,Acoustic neuroma ,medicine.disease ,Proton therapy ,Neurofibromatosis type 2 ,Radiation therapy ,030220 oncology & carcinogenesis ,Radiological weapon ,Systematic review ,Radiology ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Objective Vestibular schwannomas are benign tumors that are often managed by radiotherapy. Minimizing long-term toxicity is paramount for a population that remains at normal life expectancy and at risk for loss of quality of life for years if not decades. Whereas current radiotherapy standard utilizes photon radiation, proton radiotherapy characteristics may enable a reduction of toxicity by reducing the volume of collateral irradiated healthy tissue. A systematic review was conducted to assess tumor control and short- and long-term sequelae after proton irradiation. Methods Studies that reported on treatment outcomes of proton radiotherapy in vestibular schwannoma patients were included. Results Five peer-reviewed retrospective series met the inclusion criteria. Quality of the studies varied from low to good. There were 276 unique patients described. Tumor control rates ranged from 85 to 100% (radiological median follow-up of 2.2-7.4 years). Hearing loss rates, defined as losing Gardner Robertson class I/II hearing, showed an weighted crude average 52% (depending on follow-up duration). The weighted averages for post-irradiation facial and trigeminal neuropathy were 5% and 4%, respectively. The risk of neuropathy seems to decrease with lower radiation dosages. Conclusion Proton irradiation for vestibular schwannomas achieves high tumor control rates, equivalent to photon irradiation. Reported cranial nerve preservation rates vary, partly due to an apparent selection bias with a high percentage of patients with clinical symptoms prior to treatment. Results of cranial nerve function preservation, quality of life, and cognitive functioning are currently insufficiently reported. In addition, advances in proton radiotherapy technology warrant re-evaluation of current techniques and protocols for the management of vestibular schwannomas.
- Published
- 2019
30. Radiation Therapy Pain Management: Prevalence of Symptoms and Effectiveness of Treatment Options
- Author
-
Helen A. Shih, Brandon A. Mahal, Peggy Leland, Nayan Lamba, and Ruben Martinez
- Subjects
Male ,medicine.medical_specialty ,Nausea ,medicine.medical_treatment ,Pain ,03 medical and health sciences ,0302 clinical medicine ,Marijuana use ,Quality of life ,Internal medicine ,Prevalence ,medicine ,Humans ,Pain Management ,Aged ,Pain Measurement ,General Environmental Science ,Radiotherapy ,030504 nursing ,business.industry ,Treatment options ,Middle Aged ,Pain management ,Radiation therapy ,Opioid ,030220 oncology & carcinogenesis ,General Earth and Planetary Sciences ,Female ,medicine.symptom ,Headaches ,0305 other medical science ,business ,medicine.drug - Abstract
Background The prevalence of pain among patients undergoing radiation therapy (RT) is not well described. Objectives The purpose of this study was to assess the prevalence and management of pain in patients undergoing RT. Methods 94 patients undergoing RT were surveyed at two time points during the course of their treatment. Patients reported on pain, fatigue, nausea, headache, and depressive symptoms, as well as on the use of pharmacologic and nonpharmacologic or alternative methods for symptom management. Findings The mean severity of pain did not change significantly between the first week of RT and the final week. Severity of pain was associated with worse fatigue, nausea, headaches, and depressive symptoms, providing opportunities for providers to address multiple co-occurring symptoms. Rates of opioid and marijuana use remained similar between the two time points. More than half of the patients reported use of at least one nonpharmacologic method for pain management, with use increasing during the course of RT.
- Published
- 2019
31. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors
- Author
-
Paul W. Sperduto, Brian De, Jing Li, David Carpenter, John Kirkpatrick, Michael Milligan, Helen A. Shih, Tugce Kutuk, Rupesh Kotecha, Hajime Higaki, Manami Otsuka, Hidefumi Aoyama, Malie Bourgoin, David Roberge, Salah Dajani, Sean Sachdev, Jordan Gainey, John M. Buatti, William Breen, Paul D. Brown, Lisa Ni, Steve Braunstein, Matthew Gallitto, Tony J.C. Wang, Ryan Shanley, Emil Lou, Jay Shiao, Laurie E. Gaspar, Satoshi Tanabe, Toshimichi Nakano, Yi An, Veronica Chiang, Liang Zeng, Hany Soliman, Hesham Elhalawani, Daniel Cagney, Evan Thomas, Drexell H. Boggs, Manmeet S. Ahluwalia, and Minesh P. Mehta
- Subjects
Cancer Research ,Radiation ,Lung Neoplasms ,Brain Neoplasms ,Adenocarcinoma of Lung ,Adenocarcinoma ,Prognosis ,Small Cell Lung Carcinoma ,B7-H1 Antigen ,ErbB Receptors ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Humans ,Radiology, Nuclear Medicine and imaging ,Anaplastic Lymphoma Kinase ,Retrospective Studies - Abstract
Patients with lung cancer and brain metastases represent a markedly heterogeneous population. Accurate prognosis is essential to optimally individualize care. In prior publications, we described the graded prognostic assessment (GPA), but a GPA for patients with small cell lung cancer (SCLC) has never been reported, and in non-small cell lung cancer (NSCLC), the effect of programmed death ligand 1 (PD-L1) was unknown. The 3-fold purpose of this work is to provide the initial report of an SCLC GPA, to evaluate the effect of PD-L1 on survival in patients with NSCLC, and to update the Lung GPA accordingly.A multivariable analysis of prognostic factors and treatments associated with survival was performed on 4183 patients with lung cancer (3002 adenocarcinoma, 611 nonadenocarcinoma, 570 SCLC) with newly diagnosed brain metastases between January 1, 2015, and December 31, 2020, using a multi-institutional retrospective database. Significant variables were used to update the Lung GPA.Overall median survival for lung adenocarcinoma, SCLC, and nonadenocarcinoma was 17, 10, and 8 months, respectively, but varied widely by GPA from 2 to 52 months. In SCLC, the significant prognostic factors were age, performance status, extracranial metastases, and number of brain metastases. In NSCLC, the distribution of molecular markers among patients with lung adenocarcinoma and known primary tumor molecular status revealed alterations/expression in PD-L1 50% to 100%, PD-L1 1% to 49%, epidermal growth factor receptor, and anaplastic lymphoma kinase in 32%, 31%, 30%, and 7%, respectively. Median survival of patients with lung adenocarcinoma and brain metastases with 0, 1% to 49%, and ≥50% PD-L1 expression was 17, 19, and 24 months, respectively (P.01), confirming PD-L1 is a prognostic factor. Previously identified prognostic factors for NSCLC (epidermal growth factor receptor and anaplastic lymphoma kinase status, performance status, age, number of brain metastases, and extracranial metastases) were reaffirmed. These factors were incorporated into the updated Lung GPA with robust separation between subgroups for all histologies.Survival for patients with lung cancer and brain metastases has improved but varies widely. The initial report of a GPA for SCLC is presented. For patients with NSCLC-adenocarcinoma and brain metastases, PD-L1 is a newly identified significant prognostic factor, and the previously identified factors were reaffirmed. The updated indices establish unique criteria for SCLC, NSCLC-nonadenocarcinoma, and NSCLC-adenocarcinoma (incorporating PD-L1). The updated Lung GPA, available for free at brainmetgpa.com, provides an accurate tool to estimate survival, individualize treatment, and stratify clinical trials.
- Published
- 2021
32. SRS for Nonfunctioning Pituitary Adenomas
- Author
-
Marc R. Bussière, Jay S. Loeffler, Helen A. Shih, and Tafadzwa L. Chaunzwa
- Published
- 2021
33. Technical note: Does the greater power of pencil beam scanning reduce the need for a proton gantry? A study of head-and-neck and brain tumors
- Author
-
Susu Yan, Nicolas Depauw, Judith Adams, Bram L. Gorissen, Helen A. Shih, Jay Flanz, Thomas Bortfeld, and Hsiao‐Ming Lu
- Subjects
Brain Neoplasms ,Radiotherapy Planning, Computer-Assisted ,Proton Therapy ,Humans ,Radiotherapy Dosage ,General Medicine ,Protons - Abstract
Proton therapy systems without a gantry can be more compact and less expensive in terms of capital cost and therefore more available to a larger patient population. Would the advances in pencil beam scanning (PBS) and robotics make gantry-less treatment possible? In this study, we explore if the high-quality treatment plans can be obtained without a gantry.We recently showed that proton treatments with the patient in an upright position may be feasible with a new soft robotic immobilization device and imaging which enables multiple possible patient orientations during a treatment. In this study, we evaluate if this new treatment geometry could enable high quality treatment plans without a gantry. We created PBS treatment plans for seven patients with head-and-neck or brain tumors. Each patient was planned with two scenarios: one with a gantry with the patient in supine position and the other with a gantry-less fixed horizontal beam-line with the patient sitting upright. For the treatment plans, dose-volume-histograms (DVHs), target homogeneity index (HI), mean dose,Most of the PBS-gantry-less plans had similar target HI and organs-at-risk mean dose as compared to PBS-gantry plans and similar robustness with respect to range uncertainties and setup errors.PBS provides sufficient power to deliver high quality treatment plans without requiring a gantry for head-and-neck or brain tumors. In combination with the development of the new positioning and immobilization methods required to support this treatment geometry, this work suggests the feasibility of further development of a compact proton therapy system with a fixed horizontal beam-line to treat patients in sitting and reclined positions.
- Published
- 2021
34. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
- Author
-
Scott L. Carter, Daniel P. Cahill, Pamela S. Jones, Brian V. Nahed, Albert E. Kim, Christopher Alvarez-Breckenridge, Ugonma Chukwueke, Wendy Y. Chen, Beth Overmoyer, Matthew R. Strickland, Deborah Forst, Joana L. Mora, Nancy Wang, Maura Mahar, Jorg Dietrich, Elizabeth R. Gerstner, April F. Eichler, Eudocia Q. Lee, Justine V. Cohen, Dejan Juric, Priscilla K. Brastianos, Michael White, Anita Giobbie-Hurder, Naema Nayyar, Helen A. Shih, Kevin S. Oh, Ryan J. Sullivan, Ibiayi Dagogo-Jack, Nan Lin, and Aditya Bardia
- Subjects
Adult ,Male ,medicine.medical_specialty ,Fever ,Cancer therapy ,Science ,General Physics and Astronomy ,Phases of clinical research ,Ipilimumab ,Article ,General Biochemistry, Genetics and Molecular Biology ,Hepatitis ,Metastasis ,Antineoplastic Agents, Immunological ,Median follow-up ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Meningeal Neoplasms ,medicine ,Clinical endpoint ,Humans ,Adverse effect ,Fatigue ,Survival analysis ,Aged ,Multidisciplinary ,Brain Neoplasms ,business.industry ,Nausea ,General Chemistry ,Exanthema ,Middle Aged ,Colitis ,Survival Analysis ,Rash ,Anorexia ,Nivolumab ,Tumour immunology ,Female ,Immunotherapy ,medicine.symptom ,business ,Meningeal Carcinomatosis ,medicine.drug - Abstract
Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with a poor prognosis and limited treatment options. We present a single arm Phase II study of 18 patients with LMD receiving combined ipilimumab and nivolumab until progression or unacceptable toxicity (NCT02939300). The primary end point is overall survival at 3 months (OS3). Secondary end points include toxicity, cumulative time-to-progression at 3 months, and progression-free survival. A Simon two-stage design is used to compare a null hypothesis OS3 of 18% against an alternative of 44%. Median follow up based on patients still alive is 8.0 months (range: 0.5 to 15.9 months). The study has met its primary endpoint as 8 of 18 (OS3 0.44; 90% CI: 0.24 to 0.66) patients are alive at three months. One third of patients have experienced one (or more) grade-3 or higher adverse events. Two patients have discontinued protocol treatment due to unacceptable toxicity (hepatitis and colitis, respectively). The most frequent adverse events include fatigue (N = 7), nausea (N = 6), fever (N = 6), anorexia (N = 6) and rash (N = 6). Combined ipilimumab and nivolumab has an acceptable safety profile and demonstrates promising activity in LMD patients. Larger, multicenter clinical trials are needed to validate these results., Leptomeningeal metastases from solid tumors are a rare complication with a very poor prognosis. Here the authors report the efficacy and safety of combined ipilimumab and nivolumab in patients with leptomeningeal carcinomatosis.
- Published
- 2021
35. The Essential Anthony
- Author
-
Helen A. Shih and Phillip M. Devlin
- Subjects
Cancer Research ,Radiation ,Oncology ,business.industry ,Radiation Oncologists ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,business ,Classics - Published
- 2021
36. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
- Author
-
Priscilla K. Brastianos, Albert E. Kim, Anita Giobbie-Hurder, Eudocia Quant Lee, Nancy Wang, April F. Eichler, Ugonma Chukwueke, Deborah A. Forst, Isabel C. Arrillaga-Romany, Jorg Dietrich, Zachary Corbin, Jennifer Moliterno, Joachim Baehring, Michael White, Kevin W. Lou, Juliana Larson, Magali A. de Sauvage, Kathryn Evancic, Joana Mora, Naema Nayyar, Jay Loeffler, Kevin Oh, Helen A. Shih, William T. Curry, Daniel P. Cahill, Fred G. Barker, Elizabeth R. Gerstner, and Sandro Santagata
- Subjects
Multidisciplinary ,Disease Progression ,Meningeal Neoplasms ,Tumor Microenvironment ,General Physics and Astronomy ,Humans ,General Chemistry ,Antibodies, Monoclonal, Humanized ,Meningioma ,General Biochemistry, Genetics and Molecular Biology - Abstract
High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their aggressive phenotype. Here, we present the results of a single-arm, open-label phase 2 trial (NCT03279692) evaluating the efficacy of pembrolizumab, a PD-1 inhibitor, in a cohort of 25 evaluable patients with recurrent and progressive grade 2 and 3 meningiomas. The primary endpoint is the proportion of patients alive and progression-free at 6 months (PFS-6). Secondary endpoints include progression-free and overall survival, best intracranial response, and toxicity. Our study has met its primary endpoint and achieved a PFS-6 rate of 0.48 (90% exact CI: 0.31–0.66) and a median PFS of 7.6 months (90% CI: 3.4–12.9 months). Twenty percent of patients have experienced one (or more) grade-3 or higher treatment-related adverse events. These results suggest that pembrolizumab exerts promising efficacy on a subset of these tumors. Further studies are needed to identify the biological facets within the meningioma TME that may drive response to immune-based therapies.
- Published
- 2021
37. An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma
- Author
-
Helen A. Shih
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Adult Medulloblastoma ,business.industry ,medicine.medical_treatment ,Editorials ,MEDLINE ,Clinical Investigations ,Targeted therapy ,Internal medicine ,medicine ,Humans ,Neurology (clinical) ,Molecular Targeted Therapy ,business ,Cerebellar Neoplasms ,Medulloblastoma - Abstract
BACKGROUND: Vismodegib specifically inhibits Sonic Hedgehog (SHH). We report results of a phase I/II evaluating vismodegib + temozolomide (TMZ) in immunohistochemically defined SHH recurrent/refractory adult medulloblastoma. METHODS: TMZ-naïve patients were randomized 2:1 to receive vismodegib + TMZ (arm A) or TMZ (arm B). Patients previously treated with TMZ were enrolled in an exploratory cohort of vismodegib (arm C). If the safety run showed no excessive toxicity, a Simon’s 2-stage phase II design was planned to explore the 6-month progression-free survival (PFS-6). Stage II was to proceed if arm A PFS-6 was ≥3/9 at the end of stage I. RESULTS: A total of 24 patients were included: arm A (10), arm B (5), and arm C (9). Safety analysis showed no excessive toxicity. At the end of stage I, the PFS-6 of arm A was 20% (2/10 patients, 95% unilateral lower confidence limit: 3.7%) and the study was prematurely terminated. The overall response rates (ORR) were 40% (95% CI, 12.2-73.8) and 20% (95% CI, 0.5-71.6) in arm A and B, respectively. In arm C, PFS-6 was 37.5% (95% CI, 8.8-75.5) and ORR was 22.2% (95% CI, 2.8-60.0). Among 11 patients with an expected sensitivity according to new generation sequencing (NGS), 3 had partial response (PR), 4 remained stable disease (SD) while out of 7 potentially resistant patients, 1 had PR and 1 SD. CONCLUSION: The addition of vismodegib to TMZ did not add toxicity but failed to improve PFS-6 in SHH recurrent/refractory medulloblastoma. Prediction of sensitivity to vismodegib needs further refinements.
- Published
- 2021
38. Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas
- Author
-
Fred G. Barker, Pankaj K Agarwalla, Paul D. Brown, David A. Reardon, Adam L. Cohen, Priscilla Kaliopi Brastianos, Daniel P. Cahill, Priya Kumthekar, Erin Twohy, Jian Campian, Glenn J. Lesser, Susan Geyer, Helen A. Shih, Daniela A. Bota, Sandro Santagata, Timothy J. Kaufmann, Evanthia Galanis, Macarena I. de la Fuente, Elizabeth R. Gerstner, and Michael W. Ruff
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Clinical Sciences ,Oncology and Carcinogenesis ,Brain tumor ,Evaluation of treatments and therapeutic interventions ,Newly diagnosed ,medicine.disease ,Papillary craniopharyngioma ,Rare Diseases ,Oncology ,Clinical Research ,6.1 Pharmaceuticals ,medicine ,Genetics ,Radiology ,Oncology & Carcinogenesis ,business ,Cancer - Abstract
2000 Background: Craniopharyngiomas, a rare brain tumor along the pituitary-hypothalamic axis, can cause significant clinical sequelae. Surgery and radiation, the only effective treatments, can cause significant morbidity. Genetic analysis of craniopharyngiomas revealed that 95% of papillary craniopharyngiomas (PCP) have BRAF V600E mutations (Brastianos et al. Nature Genetics 2014). We evaluated the efficacy of BRAF/MEK inhibition in patients (pts) with previously untreated PCP. Methods: Eligible pts without prior radiation whose PCP screened positively for BRAF mutations were treated with oral vemurafenib/cobimetinib in 28-day cycles. The primary endpoint of response rate (RR) based on centrally determined volumetric data was evaluated in 16 pts, where a partial response was defined as >20% decrease in volume. This single arm, Simon two-stage phase 2 trial had 89% power to detect a true RR of at least 30% (vs. the null RR 5%; alpha=0.04). In this design, 3 or more observed volumetric responses in 16 evaluable pts would be considered promising activity. Results: In the 16 pts evaluated, 56% were female, and the median age was 49.5 years. Median follow-up was 22 months (95% CI: 16-26.5) and median number of treatment cycles was 8. Three patients progressed after therapy was discontinued and none have died. Based on volumetric response criteria, 14 of 15 pts with volumetric data available for central review had response to therapy (93%; 95% CI: 68% to 99.8%). Of 16 patients evaluable based on local review, 15 had response to therapy (93.75%; 95% CI: 70% to 99.8%). The median tumor reduction was -83% (range: -52% to -99%). The one nonresponder received 2 days of treatment before coming off therapy due to toxicity. Median progression-free survival was not reached. Grade 3 toxicities at least possibly related to treatment occurred in 12 pts (rash in 6 pts). Grade 4 toxicities were observed in two pts: hyperglycemia (n=1) and increased CPK (n=1). Three pts discontinued treatment for adverse events. Conclusions: Vemurafenib/cobimetinib resulted in an objective response in all pts who received 1 or more cycles of therapy. Our study indicates that BRAF/MEK inhibitors could be a powerful tool in the treatment of previously untreated PCP and warrants further evaluation in larger studies. A second arm of this study is enrolling pts with progressive PCP after prior radiotherapy. Support: U10CA180821, U10CA180882; U24CA196171, U10CA180868 (NRG); Genentech; https://acknowledgments.alliancefound.org. Clinical trial information: NCT03224767.
- Published
- 2021
39. Current status and recent advances in resection cavity irradiation of brain metastases
- Author
-
Nicolaus Andratschke, Simon S. Lo, Matthias Guckenberger, Maximilian Niyazi, Claus Belka, Paul D. Brown, Ivana Russo, Joshua D. Palmer, Giuseppe Minniti, Helen A. Shih, Scott G. Soltys, University of Zurich, and Minniti, Giuseppe
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,R895-920 ,Brain metastases ,Hypofractionated stereotactic radiotherapy ,Radiation necrosis ,Resection cavity ,Stereotactic radiosurgery ,610 Medicine & health ,Radiosurgery ,law.invention ,Medical physics. Medical radiology. Nuclear medicine ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,medicine ,2741 Radiology, Nuclear Medicine and Imaging ,LEPTOMENINGEAL DISEASE ,Radiology, Nuclear Medicine and imaging ,Resection Cavity ,Significant risk ,RC254-282 ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,10044 Clinic for Radiation Oncology ,Dose prescription ,Radiation therapy ,Oncology ,030220 oncology & carcinogenesis ,2730 Oncology ,Radiology ,business ,030217 neurology & neurosurgery - Abstract
Despite complete surgical resection brain metastases are at significant risk of local recurrence without additional radiation therapy. Traditionally, the addition of postoperative whole brain radiotherapy (WBRT) has been considered the standard of care on the basis of randomized studies demonstrating its efficacy in reducing the risk of recurrence in the surgical bed as well as the incidence of new distant metastases. More recently, postoperative stereotactic radiosurgery (SRS) to the surgical bed has emerged as an effective and safe treatment option for resected brain metastases. Published randomized trials have demonstrated that postoperative SRS to the resection cavity provides superior local control compared to surgery alone, and significantly decreases the risk of neurocognitive decline compared to WBRT, without detrimental effects on survival. While studies support the use of postoperative SRS to the resection cavity as the standard of care after surgery, there are several issues that need to be investigated further with the aim of improving local control and reducing the risk of leptomeningeal disease and radiation necrosis, including the optimal dose prescription/fractionation, the timing of postoperative SRS treatment, and surgical cavity target delineation. We provide a clinical overview on current status and recent advances in resection cavity irradiation of brain metastases, focusing on relevant strategies that can improve local control and minimize the risk of radiation-induced toxicity.
- Published
- 2021
40. Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non–Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification
- Author
-
Justin F. Gainor, Henning Willers, Sara Stevens, Rebecca S. Heist, and Helen A. Shih
- Subjects
Pulmonary and Respiratory Medicine ,Capmatinib ,business.industry ,Met amplification ,medicine.disease ,Gefitinib ,Oncology ,Egfr mutation ,Cancer research ,Medicine ,Non small cell ,business ,Lung cancer ,Previously treated ,medicine.drug - Published
- 2020
41. Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA)
- Author
-
Hirotake Saito, Laura Masucci, Natalie A. Lockney, Emil Lou, Sten Myrehaug, John P. Kirkpatrick, Daniel D. Tandberg, Paul W. Sperduto, Arjun Sahgal, Ayal A. Aizer, William G. Breen, Diana D. Shi, Kathryn Beal, John M. Buatti, Hidefumi Aoyama, James B. Yu, J.K. Molitoris, Tony J. C. Wang, Ryan Shanley, Laurie E. Gaspar, Albert Attia, Helen A. Shih, Veronica Chiang, David Roberge, Penny K. Sneed, Jing Li, Cheng-Chia Wu, Brent D. Cameron, Jessica Parkhurst, Michael D. Chuong, Daniel N. Cagney, Paul D. Brown, Minesh P. Mehta, Steve Braunstein, Penny Fang, and Supriya Jain
- Subjects
Oncology ,medicine.medical_specialty ,R895-920 ,macromolecular substances ,Article ,030218 nuclear medicine & medical imaging ,Medical physics. Medical radiology. Nuclear medicine ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,stomatognathic system ,Clinical Research ,Internal medicine ,parasitic diseases ,Medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,RC254-282 ,Cancer ,business.industry ,Proportional hazards model ,Hazard ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Brain metastases ,social sciences ,Prognosis ,Brain Disorders ,Gastrointestinal cancers ,3. Good health ,Clinical trial ,030220 oncology & carcinogenesis ,Cohort ,population characteristics ,Prognostic group ,Digestive Diseases ,business ,human activities ,Gi cancer ,Median survival ,End-of-life - Abstract
Highlights • Brain metastases in GI cancer patients are not uncommon. • Survival varies widely within this cohort. • New identified prognostic factors are incorporated in an updated prognostic index. • This index, the GI-GPA, will better estimate survival. • The GI-GPA is useful in treatment selection and stratification of clinical trials., Background Patients with gastrointestinal cancers and brain metastases (BM) represent a unique and heterogeneous population. Our group previously published the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with GI cancers (GI-GPA) (1985–2007, n = 209). The purpose of this study is to update the GI-GPA based on a larger contemporary database. Methods An IRB-approved consortium database analysis was performed using a multi-institutional (18), multi-national (3) cohort of 792 patients with gastrointestinal (GI) cancers, with newly-diagnosed BM diagnosed between 1/1/2006 and 12/31/2017. Survival was measured from date of first treatment for BM. Multiple Cox regression was used to select and weight prognostic factors in proportion to their hazard ratios. These factors were incorporated into the updated GI-GPA. Results Median survival (MS) varied widely by primary site and other prognostic factors. Four significant factors (KPS, age, extracranial metastases and number of BM) were used to formulate the updated GI-GPA. Overall MS for this cohort remains poor; 8 months. MS by GPA was 3, 7, 11 and 17 months for GPA 0–1, 1.5–2, 2.5–3.0 and 3.5–4.0, respectively. >30% present in the worst prognostic group (GI-GPA of ≤1.0). Conclusions Brain metastases are not uncommon in GI cancer patients and MS varies widely among them. This updated GI-GPA index improves our ability to estimate survival for these patients and will be useful for therapy selection, end-of-life decision-making and stratification for future clinical trials. A user-friendly, free, on-line app to calculate the GPA score and estimate survival for an individual patient is available at brainmetgpa.com.
- Published
- 2019
42. Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma
- Author
-
Barbara C. Fullerton, Beow Y. Yeap, Helen A. Shih, Tracy T. Batchelor, Lisa B. Nachtigall, William T. Curry, Jay S. Loeffler, Trevor J. Royce, Janet C. Sherman, Shervin Tabrizi, Michael Dworkin, J Daartz, Mary K. Colvin, and Kevin S. Oh
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Neurocognitive Disorders ,Disease ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Internal medicine ,Proton Therapy ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Radiation Injuries ,Adverse effect ,Prospective cohort study ,Proton therapy ,Brain Neoplasms ,business.industry ,Glioma ,Hematology ,Middle Aged ,Neurosecretory Systems ,Progression-Free Survival ,Radiation therapy ,030220 oncology & carcinogenesis ,Toxicity ,Disease Progression ,Quality of Life ,Female ,Neoplasm Grading ,business ,Neurocognitive - Abstract
Background Patients with low-grade gliomas (LGG) can survive years with their illness. Proton radiotherapy (PRT) can reduce off-target dose and decrease the risk of treatment-related morbidity. We examined long-term morbidity following proton therapy in this updated prospective cohort of patients with LGG. Methods Twenty patients with LGG were enrolled prospectively and received PRT to 54 Gy(RBE) in 30 fractions. Comprehensive baseline and longitudinal assessments of toxicity, neurocognitive and neuroendocrine function, quality of life, and survival outcomes were performed up to 5 years following treatment. Results Six patients died (all of disease) and six had progression of disease. Median follow-up was 6.8 years for the 14 patients alive at time of reporting. Median progression-free survival (PFS) was 4.5 years. Of tumors tested for molecular markers, 71% carried the IDH1-R132H mutation and 29% had 1p/19q co-deletion. There was no overall decline in neurocognitive function; however, a subset of five patients with reported cognitive symptoms after radiation therapy had progressively worse function by neurocognitive testing. Six patients developed neuroendocrine deficiencies, five of which received Dmax ≥20 Gy(RBE) to the hypothalamus–pituitary axis (HPA). Most long-term toxicities developed within 2 years after radiation therapy. Conclusions The majority of patients with LGG who received proton therapy retained stable cognitive and neuroendocrine function. The IDH1-R132H mutation was present in the majority, while 1p/19q loss was present in a minority. A subset of patients developed neuroendocrine deficiencies and was more common in those with higher dose to the HPA.
- Published
- 2019
43. Patterns of Failure Among Patients With Low-grade Glioma Treated With Proton Radiation Therapy
- Author
-
Michael Dworkin, Marc R. Bussière, Jay S. Loeffler, Helen A. Shih, Andrzej Niemierko, Kevin S. Oh, and Sophia C. Kamran
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Glioma ,Proton Therapy ,medicine ,Humans ,Dosimetry ,Radiology, Nuclear Medicine and imaging ,Cumulative incidence ,Young adult ,Child ,medicine.diagnostic_test ,Brain Neoplasms ,business.industry ,food and beverages ,Radiotherapy Dosage ,Magnetic resonance imaging ,Middle Aged ,medicine.disease ,Confidence interval ,Radiation therapy ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Female ,Radiology ,business - Abstract
Purpose Proton treatment may be a useful radiation therapy modality for long-term surviving patients with glioma to reduce normal tissue toxicities. Photon studies demonstrate that most low-grade glioma (LGG) failures occur within the radiation field, supporting the use of more conformal treatment plans, yet it is unclear whether this can be translated to proton radiation therapy (PRT). Our objective is to examine our institutional experience to determine patterns of failure in patients with LGG with respect to the volume irradiated with PRT. Methods and materials Patients with World Health Organization 2007 grade I to II or isocitrate dehydrogenase 1–positive mutation grade III LGG treated with PRT between 2005 and 2015 were retrospectively reviewed. Patients with documented local recurrences on magnetic resonance imaging after receipt of PRT underwent a comparison with the initial treatment plan dosimetry to evaluate patterns of failure. A total of 141 patients were included in the final cohort. Results The median follow-up time was 46.7 months (range, 2.8-144 months), and 5-year overall survival was 84%. The median PRT dose delivered was 54 Gy (relative biological effectiveness) (range, 45-60 Gy). There were 42 failures after PRT (30%). The median time to progression after treatment was 32.7 months (range, 4.8-93.6 months). Thirty-one patients (74%) failed in-field (defined as within the 95% isodose volume), 5 patients (12%) failed out-of-field, and 5 patients (12%) had marginal failures (defined as within the 50%-95% isodose volume). The 5-year freedom from progression after PRT was 60.1% (95% confidence interval, 48.7-70.0). The 5-year cumulative incidence of overall survival was 33% among those with recurrence after PRT and 96% among those without recurrence after PRT (P Conclusions Of the patients with LGG who had documented failures after PRT, most recurred within the radiation field with few marginal failures, indicating that even with PRT, which often can have steeper dose gradients, coverage is adequate. Survival was poor for patients whose tumors recurred.
- Published
- 2019
44. Hypopituitarism After Cranial Irradiation for Meningiomas: A Single-Institution Experience
- Author
-
Andrzej Niemierko, Helen A. Shih, Jay S. Loeffler, Parisa Abedi, Lisa B. Nachtigall, Barbara C. Fullerton, Kevin S. Oh, Nayan Lamba, and Marc R. Bussière
- Subjects
Adult ,Male ,Pituitary gland ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Hypopituitarism ,Thyroid Function Tests ,Thyroid function tests ,030218 nuclear medicine & medical imaging ,Growth hormone deficiency ,03 medical and health sciences ,0302 clinical medicine ,Meningeal Neoplasms ,medicine ,Adrenal insufficiency ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Aged ,Retrospective Studies ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Thyroid ,Radiotherapy Dosage ,Middle Aged ,medicine.disease ,Prolactin ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,Pituitary Gland ,030220 oncology & carcinogenesis ,Female ,Radiology ,Cranial Irradiation ,Meningioma ,business - Abstract
Patients undergoing cranial irradiation are at high risk for development of subsequent pituitary deficiencies. Patients with meningiomas can expect to live many years after treatment and are therefore particularly vulnerable to long-term sequalae of radiation therapy (RT). The purpose of this study was to determine the rates and timing of onset of pituitary dysfunction across each hypothalamic-pituitary axis in patients with meningiomas in the sellar region.Data from 74 patients with meningiomas in the sellar or perisellar region who underwent RT between 2001 and 2017 at a single academic center were analyzed. Dose-volume histograms were generated to determine the dose of radiation to the pituitary gland. Pituitary function tests were evaluated before and after completion of RT.There was a 20% risk for new hypopituitarism across any hypothalamic-pituitary axis after RT at a median follow-up of 43 months. Identified rates of dysfunction across each axis were 24% for thyroid and adrenal, 19% for growth hormone, and 10% for gonadal. Median time to develop deficiencies ranged from 11 months for growth hormone deficiency to 32 months for adrenal insufficiency. Deficiencies were likely to be correlated, with increased risk for thyroid dysfunction in patients with adrenal, gonadal, or prolactin deficiencies (P .05). On univariate analysis, mean dose to the pituitary gland and male sex were associated with increased risk for post-RT thyroid deficiency (P = .01 and P = .004, respectively). There was no difference in rates of hypothyroidism after protons compared with photons (P = .14).Cranial irradiation for sellar meningiomas carries a risk for subsequent hypopituitarism that appears to be dose dependent and may occur years after completion of RT. Growth hormone deficiency and gonadal dysfunction were likely underestimated here secondary to a lack of routine testing. Given the favorable tumor prognosis in this patient population, early and long-term endocrine follow-up is warranted.
- Published
- 2019
45. Brachytherapy as an Adjuvant for Recurrent Atypical and Malignant Meningiomas
- Author
-
Matthew J. Koch, Fred G. Barker, Trevor J. Royce, William T. Curry, Pankaj K. Agarwalla, T Mauceri, Andrezj Niemierko, Jay S. Loeffler, Kevin S. Oh, and Helen A. Shih
- Subjects
Adult ,Male ,medicine.medical_specialty ,Malignant meningioma ,medicine.medical_treatment ,Brachytherapy ,Radiosurgery ,Iodine Radioisotopes ,Meningioma ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Brain Neoplasms ,business.industry ,Postoperative radiation ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Radiation therapy ,Treatment Outcome ,Research—Human—Clinical Studies ,Cesium Radioisotopes ,030220 oncology & carcinogenesis ,Female ,Radiotherapy, Adjuvant ,Surgery ,Neurology (clinical) ,Radiology ,Neoplasm Recurrence, Local ,business ,Adjuvant ,030217 neurology & neurosurgery ,Follow-Up Studies ,Recurrent Meningioma - Abstract
BACKGROUND: Recurrent atypical and malignant meningiomas have poor outcomes with surgical therapy alone. Neither adjuvant chemotherapy nor postoperative radiation therapy remedies this problem. OBJECTIVE: To evaluate our experience with the treatment of 15 patients treated with I-125 or Cs-131 brachytherapy radiation seeds as an adjuvant in these difficult cases. METHODS: Patients with high-grade recurrent meningioma who underwent resection and intraoperative placement of brachytherapy seeds at our institution from 2002 to 2014 were identified and studied by retrospective chart review. RESULTS: Fifteen patients with median age of 68.8 yr were treated with I-125 (n = 13) or Cs-131 (n = 2) brachytherapy seeds for cases of recurrent, grade II (n = 8), or grade III (n = 7) meningioma at our institution from 2002 to 2014. These lesions originated from a variety of locations including, convexity (3), falcine (3), frontal (2), occipital (1), parietal (2), 2 sphenoid wing (2), and temporal (2), based recurrent meningiomas. Patients had a median of 2 prior open surgical interventions and received local radiation therapy with a median dose of 55 Gy prior to brachytherapy. Survival at 2.5 yr was 56% for grade II and 17% for grade III lesions. Survival was significantly associated with patient age but not tumoral pathology. Forty percent of patients required reoperations for wound complications following brachytherapy. CONCLUSION: Brachytherapy with implantation of permanent radiation seeds provides a viable alternative treatment for recurrent meningioma while carrying a significant clinical risk of wound infection and need for reoperation.
- Published
- 2019
46. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control
- Author
-
Jackson Stocking, Alexander Kaplan, Anita Giobbie-Hurder, Mia Bertalan, Christopher Alvarez-Breckenridge, Priscilla K. Brastianos, Daniel P. Cahill, Donald P. Lawrence, Corey M. Gill, Tracy T. Batchelor, Kevin S. Oh, Helen A. Shih, Naema Nayyar, Keith T. Flaherty, and Ryan J. Sullivan
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Skin Neoplasms ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Kaplan-Meier Estimate ,Radiosurgery ,Young Adult ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,CTLA-4 Antigen ,Neuro‐Oncology ,Prospective Studies ,Melanoma ,Aged ,Retrospective Studies ,Aged, 80 and over ,Brain Neoplasms ,business.industry ,Proportional hazards model ,Hazard ratio ,Age Factors ,Brain ,Retrospective cohort study ,Immunotherapy ,Middle Aged ,Prognosis ,medicine.disease ,Neoadjuvant Therapy ,Immune checkpoint ,Blockade ,Treatment Outcome ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,business ,030217 neurology & neurosurgery ,Follow-Up Studies ,Brain metastasis - Abstract
Background Immune checkpoint blockade has systemic efficacy in patients with metastatic melanoma, including those with brain metastases (MBMs). However, immunotherapy-induced intracranial tumoral inflammation can lead to neurologic compromise, requiring steroids, which abrogate the systemic efficacy of this approach. We investigated whether upfront neurosurgical resection of MBM is associated with a therapeutic advantage when performed prior to initiation of immunotherapy. Material and methods An institutional review board-approved, retrospective study identified 142 patients with MBM treated with immune checkpoint blockade between 2010 and 2016 at Massachusetts General Hospital, of whom 79 received surgery. Patients were classified based on the temporal relationship between immunotherapy, surgery, and development of central nervous system metastases. Overall survival (OS) was calculated from the date of diagnosis of MBM until death from any cause. Multivariate model building included a prognostic Cox model of OS, the effect of immunotherapy and surgical sequencing on OS, and the effect of immunotherapy and radiation sequencing on OS. Results The 2-year overall survival for patients treated with cytotoxic T-lymphocyte antigen 4, programmed death 1, or combinatorial blockade was 19%, 54%, and 57%, respectively. Among immunotherapy-naive melanoma brain metastases, surgery followed by immunotherapy had a median survival of 22.7 months (95% confidence interval [CI], 12.6-39.2) compared with 10.8 months for patients treated with immunotherapy alone (95% CI, 7.8-16.3) and 9.4 months for patients treated with immunotherapy followed by surgery (95% CI, 4.1 to ∞; p = .12). On multivariate analysis, immunotherapy-naive brain metastases treated with immunotherapy alone were associated with increased risk of death (hazard ratio, 1.72; 95% CI, 1.00-2.99) compared with immunotherapy-naive brain metastases treated with surgery followed by immunotherapy. Conclusion In treatment-naive patients, early surgical resection for local control should be considered prior to commencing immunotherapy. A prospective, randomized trial comparing the sequence of surgery and immunotherapy for treatment-naive melanoma brain metastases is warranted. Implications for practice In this retrospective study of 142 patients with melanoma brain metastases treated with immune checkpoint blockade, the development of melanoma brain metastases following immunotherapy was associated with decreased survival compared with diagnosis of immunotherapy-naive brain metastases. The benefit of surgical intervention was seen in immunotherapy-naive brain metastases in contrast to brain metastases that developed on immunotherapy. These results suggest that upfront local control with surgery for immunotherapy-naive melanoma brain metastasis may provide a bridge toward immunotherapy-mediated systemic control.
- Published
- 2019
47. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors
- Author
-
Andrew E. Sloan, Timothy C. Ryken, John S. Kuo, Christopher Alvarez-Breckenridge, Brian V. Nahed, Priscilla K. Brastianos, Mario Ammirati, Jeffrey J. Olson, Steven N. Kalkanis, and Helen A. Shih
- Subjects
Adult ,Male ,medicine.medical_specialty ,Evidence-based practice ,medicine.medical_treatment ,Tumor resection ,Recursive partitioning ,Radiosurgery ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Craniotomy ,Chemotherapy ,Performance status ,Brain Neoplasms ,business.industry ,Disease Management ,Guideline ,Congresses as Topic ,Combined Modality Therapy ,Surgery ,Neurosurgeons ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Female ,Neurology (clinical) ,Cranial Irradiation ,business ,030217 neurology & neurosurgery - Abstract
Please see the full-text version of this guideline https://www.cns.org/guidelines/guidelines-treatment-adults-metastatic-brain-tumors/chapter_2) for the target population of each recommendation listed below. SURGERY FOR METASTATIC BRAIN TUMORS AT NEW DIAGNOSIS QUESTION: Should patients with newly diagnosed metastatic brain tumors undergo surgery, stereotactic radiosurgery (SRS), or whole brain radiotherapy (WBRT)? Recommendations Level 1: Surgery + WBRT is recommended as first-line treatment in patients with single brain metastases with favorable performance status and limited extracranial disease to extend overall survival, median survival, and local control. Level 3: Surgery plus SRS is recommended to provide survival benefit in patients with metastatic brain tumors Level 3: Multimodal treatments including either surgery + WBRT + SRS boost or surgery + WBRT are recommended as alternatives to WBRT + SRS in terms of providing overall survival and local control benefits. SURGERY AND RADIATION FOR METASTATIC BRAIN TUMORS QUESTION: Should patients with newly diagnosed metastatic brain tumors undergo surgical resection followed by WBRT, SRS, or another combination of these modalities? Recommendations Level 1: Surgery + WBRT is recommended as superior treatment to WBRT alone in patients with single brain metastases. Level 3: Surgery + SRS is recommended as an alternative to treatment with SRS alone to benefit overall survival. Level 3: It is recommended that SRS alone be considered equivalent to surgery + WBRT. SURGERY FOR RECURRENT METASTATIC BRAIN TUMORS QUESTION: Should patients with recurrent metastatic brain tumors undergo surgical resection? Recommendations Level 3: Craniotomy is recommended as a treatment for intracranial recurrence after initial surgery or SRS. SURGICAL TECHNIQUE AND RECURRENCE QUESTION A: Does the surgical technique (en bloc resection or piecemeal resection) affect recurrence? Recommendation Level 3: En bloc tumor resection, as opposed to piecemeal resection, is recommended to decrease the risk of postoperative leptomeningeal disease when resecting single brain metastases. Question b Does the extent of surgical resection (gross total resection or subtotal resection) affect recurrence? Recommendation Level 3: Gross total resection is recommended over subtotal resection in recursive partitioning analysis class I patients to improve overall survival and prolong time to recurrence. The full guideline can be found at https://www.cns.org/guidelines/guidelines-treatment-adults-metastatic-brain-tumors/chapter_2.
- Published
- 2019
48. Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours
- Author
-
Mechthild Krause, Helen A. Shih, Michael H. Baumann, Armin Lühr, M.R. Bussiere, Beate Timmermann, Steffen Löck, Dirk Geismar, Xavier Vermeren, Esther G.C. Troost, Jillian E. Daly, L. Agolli, Marc R. Bussière, Almut Dutz, and Emily Schapira
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Erythema ,Proton beam therapy ,Nausea ,Medizin ,Logistic regression ,030218 nuclear medicine & medical imaging ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Proton Therapy ,Humans ,Medicine ,NTCP models ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Aged ,Probability ,Aged, 80 and over ,integumentary system ,Receiver operating characteristic ,Brain tumours ,Brain Neoplasms ,business.industry ,Hematology ,Middle Aged ,Acute side-effects ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Scalp ,Acute Disease ,Cohort ,Quality of Life ,Female ,Radiology ,medicine.symptom ,business ,Complication - Abstract
Background The limited availability of proton beam therapy (PBT) requires individual treatment selection strategies, such as based on normal tissue complication probability (NTCP). We developed and externally validated NTCP models for common acute side-effects following PBT in brain tumour patients in effort to provide guidance on optimising patient quality of life. Methods An exploration cohort including 113 adult brain tumour patients who underwent PBT was investigated for the following endpoints: alopecia, scalp erythema, headache, fatigue and nausea. Dose–volume parameters of associated normal tissues were used for logistic regression modelling. Statistically significant parameters showing high area under the receiver operating characteristic curve (AUC) values in internal cross-validation were externally validated on two cohorts of 71 and 96 patients, respectively. Results Statistically significant correlations of dose–volume parameters of the skin for erythema and alopecia were found. In internal cross-validation, the following prognostic parameters were selected: V35Gy (absolute volume receiving 35 Gy) for erythema grade ≥1, D2% (dose to 2% of the volume) for alopecia grade ≥1 and D5% for alopecia grade ≥2. Validation was successful for both cohorts with AUC >0.75. A bivariable model for fatigue grade ≥1 could not be validated externally. No correlations of dose–volume parameters of the brain were seen for headache or nausea. Conclusion We developed and successfully validated NTCP models for scalp erythema and alopecia in primary brain tumour patients treated with PBT.
- Published
- 2019
49. Fractionated Proton Beam Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial
- Author
-
L.R.G. Pike, Scott R. Plotkin, Anurag Saraf, William A. Mehan, Jay S. Loeffler, K. Franck, Nora Horick, I.S. Wang, Beow Y. Yeap, Helen A. Shih, Barbara C. Fullerton, and Michael J. McKenna
- Subjects
Cancer Research ,medicine.medical_specialty ,Radiation ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Phases of clinical research ,Stereotactic radiation therapy ,Tympanometry ,Radiosurgery ,Radiation therapy ,Auditory brainstem response ,Oncology ,Median follow-up ,otorhinolaryngologic diseases ,medicine ,Clinical endpoint ,Radiology, Nuclear Medicine and imaging ,Radiology ,business - Abstract
PURPOSE/OBJECTIVE(S) Management for vestibular schwannoma (VS) achieves excellent local control, and advances have increasingly focused on long-term serviceable hearing preservation. Fractionated stereotactic radiation therapy (FSRT) is associated with better hearing preservation compared to stereotactic radiosurgery (SRS). Fractionated proton beam radiation therapy (FPRT) may be associated with greater hearing preservation due to unique dosimetric properties of proton radiotherapy. MATERIALS/METHODS A single institution, prospective, single-arm, phase 2 clinical trial was designed for patients with VS between 2010-2019. All patients received FPRT to a total dose of 50.4-54Gy relative biological effectiveness (RBE) over 28-30 fractions. The primary endpoint was serviceable hearing preservation, defined as Gardner-Robertson (GR) score 1-2, defined as Pure Tone Average (PTA) ≤50dB and Word Recognition Score (WRS) ≥50%, at 5 years compared to a historical rate of serviceable hearing preservation of 65% in patients treated with photon radiation therapy. Other audiometric measures included Otoacoustic Emissions (OAE) and Auditory Brainstem Response (ABR). Preliminary analysis was performed for 20 patients accrued with a minimum follow up of 1.0 year. RESULTS Twenty patients were accrued with median follow up of 4.0 years (range 1.0-5.0 years), with a median age of 64 years, median RT dose of 50.4 Gy (RBE). Serviceable hearing preservation at 1 year was 53%, primary endpoint was not yet met. Local control at 4 years was 100%. Median cochlea D90 was lower for patients with serviceable hearing at 1 year (median 40.5 Gy (RBE) vs 46.9 Gy (RBE), P = 0.0863). V90, Dmean, Dmin, and other cochlea dosimetric measures were also generally lower, but the associations with hearing preservation at 1 year were not statistically significant. Median PTA at 1-year worsened from 42dB at baseline to 62dB (P < 0.0001), and median WRS at 1-year worsened significantly from 85% to 48% (P < 0.0001); PTA worsening developed earlier than WRS worsening. The rate of OAE absence significantly worsened from 60% at baseline to 100% at 1-year (P = 0.0156). Other audiometric measures, including contralateral PTA, ABR, tympanometry, were not independently associated with hearing preservation. Treatment was well tolerated, with low levels of acute and late-term toxicity; one patient incurred grade one CN V dysfunction, with no grade two or higher CN dysfunction. CONCLUSION FPRT for vestibular schwannoma results in high rates of local control with comparable serviceable hearing preservation compared to historical RT series. Audiometric analyses suggest radiation-associated hearing dysfunction is manifested as early PTA worsening followed by WRS worsening.
- Published
- 2021
50. Leptomeningeal Disease in Breast Cancer: Pre-Treatment Prognostic Factors and Outcomes
- Author
-
Diana D. Shi, Michael Milligan, Daniel N. Cagney, William A. Mehan, Beverly Moy, P. Brastianos, Nancy Wang, A. Aitelli, Helen A. Shih, Kevin S. Oh, and Nan Lin
- Subjects
Cancer Research ,medicine.medical_specialty ,education.field_of_study ,Univariate analysis ,Radiation ,business.industry ,Incidence (epidemiology) ,Medical record ,Population ,Hazard ratio ,medicine.disease ,Breast cancer ,Oncology ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Stage (cooking) ,education ,business ,Brain metastasis - Abstract
PURPOSE/OBJECTIVE(S) Leptomeningeal disease (LMD) is a devastating diagnosis with limited treatment options and poor prognosis. With recent advances in treatment, women with breast cancer (BC) are living longer and the incidence of LMD in this population is increasing. There remains little data regarding the prognosis and optimal treatment of these patients. As such, we conducted a multi-institutional retrospective review of women with BC LMD and analyzed outcomes based on prognostic factors and treatments. MATERIALS/METHODS We analyzed the records of women diagnosed with BC LMD via MRIs of their brain and/or spine between 2000 and 2020 at two academic medical centers. Demographic and clinical characteristics were abstracted from electronic medical records and an in-depth radiographic review was performed by a neuro-radiologist for each case. Univariate and multivariate Cox proportional-hazards models were generated to identify factors associated with prolonged survival. Collection and analysis of the data was approved by institutional IRB. RESULTS We identified 227 women with BC LMD. Prior to developing LMD, most women initially presented with Stage I-III BC (62.1%) with ductal histology (67.0%) and biological subtypes including ER-positive/HER2-negative (56.8%), HER2-positive (17.6%), and triple-negative (22.0%). LMD was first diagnosed a median of 4.6 years (range: 0 to 34.1 years) after the initial diagnosis of BC, and the median age at LMD diagnosis was 54.6 years (range: 29.4 to 84.5 years). At time of LMD diagnosis, 146 (64.3%) women presented with a Karnofsky Performance Status (KPS) ≥ 70, 90 (39.6%) had a preceding parenchymal brain metastasis, and 23 (10.1%) had LMD as their only site of metastatic disease. Radiographically, classical LMD (61.7%) was observed more frequently than nodular-only LMD (13.2%). Brain-only LMD was present in 55.1% of patients, spine-only in 6.1% of patients, and both brain and spine in 38.8% of patients. Median survival from the time of LMD diagnosis was 4.5 months (95% CI: 3.4-7.8). Pre-treatment clinical factors associated with improved survival on univariate analysis included ER-positive/HER2-negative subtype (P = 0.010), KPS ≥ 70 (P < 0.001), LMD as the only site of metastasis (P = 0.004), stable or controlled extracranial metastases (P = 0.042), absence of leukopenia (P = 0.040) and the presence of nodular LMD (P < 0.001). After adjusting for these clinical factors, the receipt of radiation therapy (adjusted hazard ratio [AHR] 0.50, 95% CI: 0.37 - 0.68), systemic therapy (AHR 0.27, 95% CI: 0.19 - 0.38) and intrathecal chemotherapy (AHR 0.49, 95% CI: 0.33 - 0.75) were all associated with improved survival. CONCLUSION In one of the largest multi-institutional reviews to date, we found that several pre-treatment clinical factors were significantly associated with improved survival among women with breast cancer LMD. However, despite treatment overall survival remains poor, and there is a need for new, effective therapies. AUTHOR DISCLOSURE M.G. Milligan: None. A. Aitelli: None. W.A. Mehan: Consultant; Kura Oncology. D.D. Shi: None. D.N. Cagney: Research Grant; Viewray, NhTheraguix. K.S. Oh: None. N. Wang: None. P. Brastianos: Research Grant; Merck, Eli Lily, BMS. Honoraria; Merck, Genentech. Consultant; Angiochem, Dantari Pharmaceuticals, Elevatebio, Eli Lily, Genentech, Pfizer, SK Life Sciences, Tesaro. B. Moy: Research Grant; PUMA biotechnology. N.U. Lin: Research Grant; Genentech, Merck, Pfizer, Seattle Genetics. Consultant; PUMA Biotechnology, Seattle Genetics, Daiichi Sankyo, Astra Zeneca, Denali Therapeutics, California Institute for Regenerative Medicine, Prelude Therapeutics. H.A. Shih: Employee; Dartmouth Hitchcock. Research Grant; AbbVie, NIH. Honoraria; UpToDate. Consultant; Cleveland Clinic. Speaker's Bureau; prIME Oncology. advisory; The Radiosurgery Society. director of clinical operations; Massachusetts General Hospital. clinical operational leader; Massachusetts General Hospital.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.